Evista, Raloxifene News

We read with great interest the subgroup analyses of the Raloxifene use for the Heart trial.1 Although this post hoc analysis did not show benefit of raloxifene for any prespecified group, we believe that one particular subgroup, not defined in this study, may benefit from raloxifene in the reduction of coronary outcomes.

You cannot control some things that put you at risk for breast cancer , such as your age and being female.

Eli Lilly & Co. lost a bid for a hearing before Canadaa s highest court on whether its patent for the Evista osteoporosis treatment is valid as the company tried to block Apotex Inc.

My mother ,71 years old, has been use Steroid drug for serious Asthma for many years.

In his article about chemoprevention of breast cancer, Dr. Goldstein provided relative-risk tables.

Canada: The Federal Court Of Appeal Recently Released An Important Decision On The Doctrine Of Sound Prediction and David Tait Facts Eli Lilly's '356 patent claims raloxifene and other benzothiophenes for use in treating or preventing osteoporosis or bone loss, particularly in post-menopausal females, and particularly without eliciting significant ...

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version.

A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.'s drug Evista, the company announced late yesterday.

Eli Lilly & Co. won a ruling on the validity of patents for its Evista osteoporosis treatment, blocking an attempt by Teva Pharmaceutical Industries Ltd.

The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's method-of-use patents on Evista .

Earnings Estimates Revisions They're the most powerful force driving stock prices, and the key to the Zacks Rank's market-beating track record.

Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality , U.S. Department of Health & Human Services.

Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality , U.S. Department of Health & Human Services.

Women at high risk of breast cancer can often lower that risk by taking medication, including drugs like tamoxifen or the osteoporosis drug raloxifene .

DEAR DR. DONOHUE: My doctor recently put me on Evista. I had a complete hysterectomy when I was 40 years old.

Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from the Department of Health & Human Services' Agency for Healthcare Research and Quality .

Some of us are doing well on our osteoporosis treatment and some of us aren't. For those who aren't seeing gains in bone density, this can be extremely discouraging and we'd like to come up with some ideas for you that may help.

I am concerned about a decision I have to make soon regarding Reclast or Forteo for my osteopenia.

As they pursue home run products, drugmakers also seek the pharmaceutical equivalents of a baseball utility infielder -- a compound that works on several diseases or conditions.

TOKYO, Gurgaon, India, September 1, 2009 - Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited announced today that Terapia S.A. , a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication, Evista in Romania.